loading
Supernus Pharmaceuticals Inc stock is traded at $54.56, with a volume of 459.59K. It is down -3.53% in the last 24 hours and up +14.05% over the past month. Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
See More
Previous Close:
$56.50
Open:
$56.33
24h Volume:
459.59K
Relative Volume:
0.56
Market Cap:
$3.06B
Revenue:
$665.13M
Net Income/Loss:
$64.50M
P/E Ratio:
47.69
EPS:
1.1442
Net Cash Flow:
$185.87M
1W Performance:
+3.17%
1M Performance:
+14.05%
6M Performance:
+67.81%
1Y Performance:
+59.98%
1-Day Range:
Value
$54.21
$57.33
1-Week Range:
Value
$51.84
$57.65
52-Week Range:
Value
$29.16
$57.65

Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile

Name
Name
Supernus Pharmaceuticals Inc
Name
Phone
301-838-2500
Name
Address
9715 KEY WEST AVENUE, ROCKVILLE, MD
Name
Employee
674
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
SUPN's Discussions on Twitter

Compare SUPN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
SUPN
Supernus Pharmaceuticals Inc
54.58 3.17B 665.13M 64.50M 185.87M 1.1442
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
143.87 63.86B 9.39B 2.62B 2.22B 5.8121
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.37 41.80B 29.96B 957.25M 4.77B 0.2956
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.24 40.88B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
20.14 22.98B 16.70B -157.13M 1.19B -0.1446
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
444.10 19.53B 3.08B 1.24B 1.07B 25.61

Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-09-25 Upgrade Piper Sandler Neutral → Overweight
Jul-30-25 Upgrade Cantor Fitzgerald Neutral → Overweight
Feb-19-25 Downgrade Cantor Fitzgerald Overweight → Neutral
Jan-06-25 Initiated Cantor Fitzgerald Overweight
Sep-11-24 Downgrade Piper Sandler Overweight → Neutral
Jan-03-23 Resumed Jefferies Buy
Dec-01-21 Resumed Jefferies Buy
Apr-13-21 Upgrade Jefferies Hold → Buy
Jun-16-20 Upgrade Piper Sandler Neutral → Overweight
Jun-15-20 Resumed Jefferies Hold
Nov-08-19 Downgrade Berenberg Buy → Hold
Nov-07-19 Downgrade Stifel Buy → Hold
Nov-06-19 Downgrade Jefferies Buy → Hold
Nov-12-18 Reiterated B. Riley FBR Buy
Jan-18-18 Reiterated B. Riley FBR, Inc. Buy
Dec-28-17 Reiterated B. Riley FBR, Inc. Buy
Dec-04-17 Upgrade Janney Neutral → Buy
Nov-08-17 Upgrade Stifel Hold → Buy
Oct-19-17 Initiated FBR & Co. Buy
Sep-19-17 Downgrade Stifel Buy → Hold
Jul-17-17 Downgrade Piper Jaffray Overweight → Neutral
Jul-14-17 Initiated Janney Neutral
Jun-01-17 Upgrade Piper Jaffray Neutral → Overweight
Jul-18-16 Downgrade Northland Capital Outperform → Market Perform
Jul-18-16 Downgrade Piper Jaffray Overweight → Neutral
Feb-08-16 Upgrade Jefferies Hold → Buy
Nov-05-15 Reiterated Northland Capital Outperform
Oct-28-15 Initiated Northland Capital Outperform
View All

Supernus Pharmaceuticals Inc Stock (SUPN) Latest News

pulisher
07:44 AM

Supernus a new buy at BofA on 'underappreciated' CNS assets - MSN

07:44 AM
pulisher
12:20 PM

Can Supernus Pharmaceuticals Inc. stock continue upward trendPortfolio Performance Report & Long Hold Capital Preservation Plans - newser.com

12:20 PM
pulisher
12:16 PM

Why Supernus Pharmaceuticals Inc. stock remains undervaluedBond Market & AI Forecasted Entry and Exit Points - newser.com

12:16 PM
pulisher
Oct 30, 2025

Supernus Pharmaceuticals Hits New 52-Week High of $55.95 - Markets Mojo

Oct 30, 2025
pulisher
Oct 30, 2025

Supernus Pharmaceuticals Inc. stock trendline breakdownJuly 2025 Update & Consistent Profit Alerts - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

How to monitor Supernus Pharmaceuticals Inc. with trend dashboardsJuly 2025 Price Swings & High Conviction Trade Alerts - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Long term hold vs stop loss in Supernus Pharmaceuticals Inc.IPO Watch & Risk Controlled Swing Alerts - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Top chart patterns to watch in Supernus Pharmaceuticals Inc.Watch List & Verified Short-Term Plans - newser.com

Oct 30, 2025
pulisher
Oct 29, 2025

What institutional flow reveals about Supernus Pharmaceuticals Inc.Treasury Yields & Community Verified Trade Alerts - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

Supernus Pharmaceuticals Inc Stock Analysis and ForecastQuarterly Earnings Review & Rapid Portfolio Appreciation - earlytimes.in

Oct 29, 2025
pulisher
Oct 29, 2025

Supernus Pharmaceuticals (SUPN) Gains Market Attention with Key CNS Drugs - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Here's Why Supernus Pharmaceuticals (SUPN) is a Great Momentum Stock to Buy - sharewise.com

Oct 29, 2025
pulisher
Oct 29, 2025

Can Supernus Pharmaceuticals Sustain Momentum After 13% Jump on Neuroscience Pipeline News? - Yahoo Finance

Oct 29, 2025
pulisher
Oct 29, 2025

Supernus Pharmaceuticals Hits New 52-Week High of $53.28 - Markets Mojo

Oct 29, 2025
pulisher
Oct 29, 2025

BofA Securities Initiates Supernus Pharmaceuticals at Buy With $65 Price Target - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

B of A Securities Initiates Coverage on SUPN with a Buy Rating | - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Supernus Pharmaceuticals (SUPN) Price Target Increased by 32.88% to 59.36 - Nasdaq

Oct 29, 2025
pulisher
Oct 29, 2025

B of A Securities Initiates Coverage of Supernus Pharmaceuticals (SUPN) with Buy Recommendation - Nasdaq

Oct 29, 2025
pulisher
Oct 29, 2025

Is Supernus Pharmaceuticals Inc. stock near bottom after decline2025 Winners & Losers & Weekly Consistent Profit Watchlists - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

Using data models to predict Supernus Pharmaceuticals Inc. stock movementTrade Analysis Summary & Safe Entry Trade Reports - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

It’s Clear How Big Money Flows Lift Supernus - Yahoo Finance

Oct 29, 2025
pulisher
Oct 28, 2025

Will Supernus Pharmaceuticals Inc. stock gain from lower inflationJuly 2025 Selloffs & Safe Entry Point Alerts - Fundação Cultural do Pará

Oct 28, 2025
pulisher
Oct 28, 2025

Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline - sharewise.com

Oct 28, 2025
pulisher
Oct 28, 2025

Is Supernus Pharmaceuticals Inc. stock supported by strong fundamentalsWeekly Investment Summary & Smart Swing Trading Alerts - Fundação Cultural do Pará

Oct 28, 2025
pulisher
Oct 27, 2025

Is Supernus Pharmaceuticals Inc. stock attractive after correctionEntry Point & Low Drawdown Trading Strategies - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Advanced analytics toolkit walkthrough for Supernus Pharmaceuticals Inc.2025 Year in Review & Daily Profit Maximizing Tips - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? - sharewise.com

Oct 27, 2025
pulisher
Oct 27, 2025

Sentiment analysis tools applied to Supernus Pharmaceuticals Inc.2025 Investor Takeaways & Risk Managed Trade Strategies - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

How Supernus Pharmaceuticals Inc. stock reacts to Fed rate cutsTrade Volume Summary & Weekly Stock Breakout Alerts - newser.com

Oct 27, 2025

Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Supernus Pharmaceuticals Inc Stock (SUPN) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Khattar Jack A.
President, CEO
Oct 09 '25
Sale
50.57
59,900
3,029,336
1,206,578
NEWHALL CHARLES W III
Director
Oct 09 '25
Sale
50.77
25,000
1,269,234
104,644
$45.65
price up icon 3.68%
drug_manufacturers_specialty_generic RDY
$13.29
price down icon 1.14%
$22.49
price down icon 0.29%
$10.35
price down icon 0.19%
$141.84
price up icon 2.67%
$442.96
price down icon 2.21%
Cap:     |  Volume (24h):